NewsBenzingaFortress Biotech: l’EPS del terzo trimestre a $(0,23) non raggiunge la stima di $(0,15), ricavi a $19,159 milioni sotto la stima di $21,575 milioni Fortress Biotech: l’EPS del terzo trimestre a $(0,23) non raggiunge la stima di $(0,15), ricavi a $19,159 milioni sotto la stima di $21,575 milioni Benzinga 2026.11.13 13:15 (GMT+0) Open on Benzinga Other news Swoosh and a Miss: Nike Investor Day Leaves Wall Street Cold-Footed Wall Street Says the AI Trade Is Over — ETF Investors Aren’t Acting Like It Citigroup Maintains Neutral on Westlake, Lowers Price Target to $65 Citigroup Maintains Neutral on LyondellBasell Industries, Lowers Price Target to $66 Caterpillar's 'Best-In-Class' Construction Business Is Getting Overlooked, Analyst Says How to Play NKE Stock as Nike Risks Becoming a Forever Turnaround Story